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A B S T R A C T   
Purpose: To describe the baseline participant characteristics in the ASPREE-AMD study, investigating the effect of 
aspirin on AMD incidence and progression. 
Methods: Australian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized 
to 100 mg aspirin daily or placebo, had non-mydriatic, digital color fundus images graded according to the 
Beckman AMD classification. Associations with AMD were determined for baseline characteristics and genetic 
risk variants. 
Results: ASPREE-AMD sub-study enrolled 4993 participants with gradable macular images. Median age was 73.4 
years (IQR, 71.5, 76.6), 52% were female, 10% had diabetes mellitus, 73% had hypertension, and 44% were 
former/current smokers. Early, intermediate and late AMD (detected in 20.6%, 16.1%, 1.1%, respectively), 
significantly associated with age, were also associated with increasing HDL levels: OR = 1.52 (95%CI, 1.26, 
1.84), OR = 1.43 (1.17, 1.77) and OR = 1.96 (1.02, 3.76), respectively. Female sex was associated with early 
[OR = 1.37 (1.16, 1.62)], and intermediate [OR = 1.35 (1.12, 1.63)] AMD, as was previous regular use of aspirin, 
with OR = 1.46 (1.11, 1.92) and OR = 1.37 (1.01, 1.85), respectively. Current smoking had increased odds for 
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late AMD, OR = 4.02 (1.42, 11.36). Genetic risk variant rs3750846 (ARMS2/HTRA1) was associated with each 
AMD stage (p < 0.001), risk variants rs570618 and rs10922109 (CFH) with intermediate and late AMD (p <
0.001), and rare variant rs147859257 (C3) with late AMD (p < 0.001). The randomized groups were well 
balanced for all analyzed AMD risk factors. 
Conclusions: Observed associations are typical of AMD. The ASPREE-AMD clinical trial provides a unique op-
portunity to determine the risks and benefits of low-dose aspirin for AMD incidence and progression in elderly 
population. 
Trial registration: Australian New Zealand Clinical Trial Registry: ACTRN 12613000755730.   
1. Introduction 
The prevalence and incidence of age-related macular degeneration 
(AMD) are increasing as a result of the increasing proportion of elderly 
individuals in the population and this has a substantial impact on quality 
of life and the costs of care [1–7]. The absence of specific treatments that 
prevent progression from early to late stages of AMD (which threaten 
central vision), necessitates a search for measures that may delay the 
onset of this chronic disease or slow its progression. 
The detailed rationale for the ASPREE-AMD study has been described 
previously [8]. In brief, aspirin has been considered of potential benefit 
in AMD because of its anti-inflammatory properties that could reduce 
low-grade inflammation in the earlier stages of AMD [9–15]. However, 
aspirin could also exacerbate retinal hemorrhages in late AMD [16–21]. 
Consistent with this paradox, previous observational and experimental 
studies in AMD have reported differing results related to risks and 
benefits of aspirin [14–19,21–34]. Meta-analyses have similarly not 
yielded definitive conclusions [20,35–37]. Therefore, given the wide-
spread use of aspirin by older persons, a well-designed randomized 
controlled clinical trial of sufficient size and duration is needed [38–42]. 
The ASPirin in Reducing Events in the Elderly (ASPREE) primary 
prevention randomized controlled trial (2010–2017) provided the op-
portunity to undertake the ASPREE-AMD sub-study [43,44]. ASPREE 
investigated the risks and benefits of daily low-dose aspirin on a primary 
composite endpoint of disability- and dementia-free survival [45], and 
also mortality [46], cardiovascular events, major bleeding [47] and 
selected other conditions in 19,114 older participants [48–53]. The 
aspirin intervention was terminated after a median of 4.7 (interquartile 
range, 3.6 to 5.7) years of follow up in June 2017, for lack of benefit for 
the primary endpoint, disability-free and dementia-free survival, and 
higher rates of major hemorrhages and all-cause mortality [45–47]. 
Nonetheless, the ASPREE-AMD sub-study continued collecting the 
5-year follow up retinal images (2016–2020) in order to investigate any 
possible delayed effect of long-term low-dose aspirin. Those measure-
ments made after June 2017 have been flagged and sensitivity analyses 
will be undertaken with and without including these ‘post-intervention’ 
measures. 
After completion of the primary ASPREE study in June 2017, its 
cohort is followed up in observational mode until 2024 as the ASPREE- 
XT (ASPREE-extension) study. Funded by the NHMRC and NIH/NIA, 
this study provides a substantial basis for the ASPREE-AMD sub-study by 
maintaining the infrastructure and database, providing scientific and 
administrative support, tracking the location of participants, and 
continuing uninterrupted collection of the data on adverse events, 
change of medications, morbidity, and mortality. 
Here, we describe the baseline characteristics of ASPREE-AMD par-
ticipants and associations between demographics, lifestyle, clinical and 
genetic risk factors and AMD stages in this cohort. 
2. Materials and methods 
The detailed methodologies of the principal ASPREE study [43,54] 
and the ASPREE-AMD sub-study [8] have been published previously. In 
brief, ASPREE was a multi-centre, randomized, double-blinded, place-
bo-controlled trial of daily 100 mg enteric-coated aspirin in 19,114 older 
adults in both Australia and the USA [43]. In Australia, participants 
were healthy individuals who were 70 years and older, free of docu-
mented evidence of cardiovascular disease, cognitive impairment or 
physical disability and without a contraindication for aspirin use. 
2.1. ASPREE-AMD sub-study 
The Australian ASPREE participants were the recruitment source for 
the ASPREE-AMD study. The ASPREE-AMD sub-study involved acqui-
sition of non-mydriatic digital retinal images of both eyes from the 
ASPREE participants at baseline and after 3 and 5 years of follow up. All 
ASPREE study inclusion and exclusion criteria applied to this sub-study, 
with the additional inclusion criterion of having gradable images of the 
macular area in at least one eye. 
Study enrolment retinal photography was conducted between March 
2010 and January 2015. The approved time frame for image collection 
from an individual participant was from 6 months before to 3 months 
after their randomization date. Bilateral digital 45◦ color fundus pho-
tographs, centered on the macula and optic disc, were captured using 
Canon Non-Mydriatic fundus cameras (Canon Inc., Tokyo, Japan) with 
Digital Health Care software (UK). Digital images were viewed imme-
diately and repeated if necessary. 
All images were graded by two senior graders from the Centre for Eye 
Research Australia (CERA), according to the Beckman classification 
system, which is based upon the stage of disease in the worse affected 
eye [55]. The following Beckman risk categories of AMD will be used in 
the analysis:  
• No apparent aging change: no drusen and no AMD pigmentation 
abnormalities  
• Normal aging changes: only drupelets (small drusen <63 μm) and no 
AMD pigmentation abnormalities  
• Early AMD: Medium drusen (≥63 μm – <125 μm) with no AMD 
pigmentation abnormalities  
• Intermediate AMD: Medium drusen (≥63 μm – <125 μm) with AMD 
pigmentation abnormalities or large drusen (≥125 μm)  
• Advanced AMD: neovascular AMD (nAMD) or geographic atrophy 
This severity scale will be used to define primary outcomes, which 
are the incidence and progression of AMD per person [8]. In addition, 
exploratory outcomes will be the rate of retinal hemorrhages and 
whether other factors, such as genotype, systemic disease, inflammatory 
biomarkers, or comorbidity influence the effect of aspirin on the course 
of AMD. 
All cases of late AMD were adjudicated by clinical specialists. The 
graders had previously reported good intra- and inter-grader agreement 
in AMD grading, with kappa statistics ranging from 0.60 to 1.00 [56]. 
Graders showed high intra-grader repeatability for the separate AMD 
features, which varied from the direct agreement of 89% (kappa = 0.81) 
and 82% (kappa = 0.69) for intermediate and large drusen, respectively, 
to 99% (kappa = 0.97) for the most advanced form of late AMD – 
choroidal neovascularization (CNV). Inter-grader repeatability varied 
from 86% agreement (kappa = 0.72) for intermediate drusen to 97% 
(kappa = 0.65 or 0.68) for late AMD features. In testing for a temporal 
drift in grading, the overall person-based determination of AMD stages, 
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according to the Beckman classification, was in direct agreement in 89% 
(kappa = 0.845). The measures of agreement were obtained before 
adjudication was provided. 
2.2. Data collection and ethics approval 
This study is collaboration between the School of Public Health and 
Preventive Medicine at Monash University, which coordinated the 
ASPREE study, including recruitment of participants and collection of 
demographic, anthropometric, lifestyle and clinical data, as well as 
blood samples and retinal images, and CERA, which graded macular 
photos for AMD and other pathology, and validated ophthalmic infor-
mation. All participants signed a written informed consent form after 
explanation of the ASPREE-AMD study. 
The ASPREE-AMD study protocol was approved by the Human 
Research and Ethics Committee of Monash University (MUHREC), un-
dertaken according to the Helsinki Declaration for research on humans 
and registered with the Australian New Zealand Clinical Trial Registry: 
ACTRN 12613000755730. The ASPREE study was also registered with 
the International Standardized Randomized Controlled Trials Register, 
ASPirin in Reducing Events in the Elderly, Number: ISRCTN83772183 
and clinicaltrials.gov, Number NCT01038583. Three additional sub- 
studies of ASPREE, ENVISion (Aspirin for the prevention of cognitive 
decline in the Elderly: a Neuro-Vascular Imaging Study, 
ACTRN12609000613202) [57], SNORE-ASA (Study of Neurocognitive 
Outcomes, Radiological and retinal Effects of Aspirin in Sleep Apnea, 
ANZCTRN12612000891820) [52], and the ASPREE Healthy Ageing 
Biobank, also contributed images to the ASPREE-AMD study. These 
sub-studies used the same methodology for fundus imaging as the 
ASPREE-AMD study. Written informed consents for retinal imaging were 
taken for all four contributing sub-studies of ASPREE. In addition, 
MUHREC approved the use of quality color images taken with the same 
method and provided by optometrists for those ASPREE participants 
who were willing to participate but for whom retinal photography by the 
study staff was not possible. Genetic analysis of stored blood samples 
from the ASPREE Healthy Ageing Biobank was approved by the Alfred 
Hospital Human Research Ethics Committee. 
2.3. Genetic data 
Genotyping was undertaken using the Axiom™ Precision Medicine 
Diversity Array (Thermo Fisher) following standard protocols at the 
Ramaciotti Centre for Genomics. Imputation of genetic variants was 
performed on European-ancestry samples using the haplotype reference 
consortium (HRC) panel on the Michigan imputation server [58]. In post 
imputation quality control step all single nucleotide polymorphisms 
(SNPs) < 0.3 imputation quality scores were excluded from further 
downstream analysis. Of the 52 SNPs previously associated with AMD 
[59], 40 imputed genetic variants were available for further analysis. 
The remaining 12 variants were not present in the ASPREE imputed 
genotype data because they were not included in the microarray of the 
whole ASPREE cohort. 
2.4. Statistical analysis 
Descriptive statistics included median ± interquartile range for 
continuous variables, or number (frequency %) for categorical variables. 
Multinomial logistic regression was used to study the association be-
tween AMD stages at baseline and selected factors reflecting de-
mographics, general health and lifestyle. In this statistical model, AMD 
grade was considered as a nominal outcome variable with 4 categories: 
None/Normal ageing changes (No AMD), Early AMD, Intermediate AMD 
and Late AMD. All analyses were performed using R version 3.6.1 [60]. 
The variables of potential relevance to the risk of AMD included age 
and sex, lifestyle and general health characteristics: smoking, alcohol 
use, body-mass index (BMI), educational levels, non-fasting glucose, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total 
cholesterol levels, history of diabetes mellitus or hypertension and 
previous regular use (irrespective of dose, frequency or longevity of use) 
of aspirin or statin, the latter defined as any medication whose ATC code 
places it in the statin group of medications, as statins may also have the 
potential to influence development of AMD [61]. 
Variable definitions: Diabetes mellitus is defined as self-report of 
diabetes or fasting glucose ≥126 mg/dL or on treatment for diabetes; 
Hypertension is defined as SBP ≥140 mmHg or DBP ≥90 mmHg or on 
treatment for high blood pressure. Body-mass index (weight in kilo-
grams divided by the square of the height in meters) categories: <20 
(underweight), 20–24 (normal weight), 25 to 29 (overweight), or ≥30 
(obese); Smoking History is defined as smoking (Current), having 
smoked (Former) or never having smoked (Never) on average equal or 
more than one cigarette/cigar/pipe a day; Alcohol use is defined as 
having (Current), having had (Former) or never having had (Never) at 
least one alcoholic drink per week; non-fasting glucose, HDL, LDL and 
total cholesterol levels are continuous variables. 
The participant’s awareness of having AMD prior to study entry was 
also recorded. 
Extraction of genetic data and independent logistic regression anal-
ysis for each AMD stage (early, intermediate and late) versus controls 
(no AMD) was undertaken using the plink software (version 1.09) [62, 
63]. We corrected for multiple testing using Bonferroni correction, and 
considered p values < 0.001 to be statistically significant. 
It was estimated that a sample of 5000 participants, with gradable 
images at baseline and 4% per annum loss to follow-up, would provide 
80% power with two-sided alpha of 0.05 to detect: (1) 24% reduction of 
early/intermediate AMD incidence, (2) 20% reduction of progression 
from early to intermediate stage of disease and (3) 53% reduction of 
progression from early or intermediate stage to late stage [8]. 
3. Results 
3.1. Participants 
A total of 14,247 of 16,703 participants from the ASPREE study in 
Australia consented to retinal photography. Given that ASPREE 
recruitment occurred throughout an extensive area of south-eastern 
Australia, facilities, geographic and scheduling limitations allowed 
collection of retinal images from only 5422 ASPREE participants. Of 
these, 4993 participants with gradable images in at least one eye were 
included for longitudinal follow up, and 4387/4993 (88%) of these 
participants had gradable images from both eyes. In some participants, 
small pupil size, along with increased nuclear density, made it impos-
sible to take retinal images of gradable quality. Images with either poor 
focus or field or with a confounding lesion or artefact obscuring the 
macula were defined as ungradable. In 82/4993 (1.6%) cases the 
gradable images were provided by the participants’ local eye care 
providers. 
Fig. 1 outlines ASPREE-AMD recruitment, from the total number of 
Australians recruited to ASPREE to the sample of participants with 
gradable retinal images included in the ASPREE-AMD study. 
3.2. Baseline characteristics 
At the time of randomization, 69% of the photographed participants 
lived in capital cities and 31% lived in regional centers or rural areas of 
five south-eastern states and territories of Australia. 
The median age of the 4993 enrolled participants was 73.4 years 
(IQR 71.5, 76.6) and 52% were women, 10% had diabetes mellitus, 73% 
had hypertension, 44% were former/current smokers, 46% were over-
weight, 29% were obese and 44% had less than 12 years of education. 
7% of participants reported regular use of aspirin prior to entering the 
study, which they stopped in order to commence the study medication, 
and 31% were on prescribed statin medications. Only 4% reported 
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having been told by a doctor of having AMD. The overall prevalence of 
early, intermediate and late AMD at baseline was 20.6%, 16.1% and 
1.1%, respectively, with no significant difference in distribution of 
stages between the groups allocated to placebo and aspirin (p < 0.53). 
Of the 11,710 Australian ASPREE participants not participating in 
the ASPREE-AMD study, their median age was one year older (74.3 vs 
73.4), more frequently they were females (56% vs 52%); greater pro-
portions had less than 12 years of education (53% vs 44%), were un-
derweight (2% vs 1%), had hypertension (76% vs 73%), never 
consumed alcohol (17% vs 14%) and were aware of having AMD (9% vs 
4%) than the 4993 who were included in the ASPREE-AMD study. Only 
those characteristics that had statistically significant differences have 
been cited. 
Of the 327 excluded participants whose non-mydriatic fundus im-
ages were of insufficient quality in both eyes, the median age was two 
year older (75.3 vs. 73.4), and proportion of males was greater (55% vs 
48%) compare to the study participants with gradable images at base-
line. In other characteristics they were not significantly different from 
the analyzed sample. 
The baseline characteristics are summarized by the stages of AMD in 
Table 1. Women were more likely to have AMD than men (43% vs 33%, 
respectively). Prevalence of late AMD was higher in current smokers 
(3%) and underweight participants (4%), compared with the rest of the 
sample (1% for both factors). The previous regular users of aspirin had a 
higher prevalence of early and intermediate AMD than non-users (26% 
and 19% versus 20% and 16%, respectively). There were almost equal 
proportions of the AMD stages amongst users and non-users of statin. 
The data on the awareness of having AMD was available from only 57% 
of the sample. Awareness of having AMD increased with increasing 
severity of the disease. Thus, 17/577 (3%) of participants with early 
AMD, 45/460 (10%) of participants with intermediate AMD and 34/42 
(81%) of participants with late AMD were aware of having signs of AMD. 
Of interest, 31/1749 (1.8%) of participants without signs of AMD on 
their fundus images believed they had been told they had AMD. There 
were no obvious differences in distributions of other risk factors or 
comorbidities across AMD stages. 
Fig. 1. ASPREE-AMD study CONSORT Flow Diagram.  
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3.3. Associations between the baseline characteristics and AMD stages 
The results of univariable and multivariable multinomial logistic 
regression analysis of the associations between the baseline character-
istics and AMD stages are presented in Table 2 and Table 3. Each stage of 
AMD was significantly associated with increasing age, with OR = 1.03, 
OR = 1.08 and OR = 1.23 for early, intermediate and late AMD, 
respectively. Females were more likely than males to have early and 
intermediate AMD, OR = 1.37 and OR = 1.35, respectively. Higher HDL 
levels were associated with all stages of AMD (OR = 1.52, OR = 1.43 and 
OR = 1.96, respectively), whereas LDL and total cholesterol levels were 
not associated with AMD. Current smokers were more likely to have late 
AMD (OR = 4.02) compared to non-smokers, whilst current or former 
alcohol use, hypertension or diabetes were not associated with any stage 
of AMD. Those participants who had taken aspirin on a regular basis 
prior to enrolment were more likely to have early or intermediate AMD 
(OR = 1.46 and OR = 1.37, respectively) than those who were not taking 
aspirin. The use of statin medications was not associated with any stage 
of AMD. Underweight participants were more likely to have late AMD in 
the univariable analysis, with OR = 3.97, but after adjusting for other 
variables in multivariable analysis, the association between low body 
weight and late AMD was no longer statistically significant. All other 
characteristics showed no statistically significant association with AMD. 
3.4. Genetic analysis 
Of the 52 SNPs previously associated with AMD [59], we were able to 
generate post-QC genotyping on 40 variants in 4391 ASPREE-AMD 
samples. The overall genotyping rate was greater than 95% for the 40 
AMD risk variants genotyped across 2735 ‘No AMD’ (62%), 903 early 
(21%), 705 intermediate (16%) and 48 late (1%) AMD samples (Sup-
plementary Table). Four SNPs were associated with one or more stages 
of AMD after correction for multiple testing (p ≤ 0.001) (Table 4). These 
included rs3750846 at the ARMS2/HTRA1 loci, in high Linkage 
Disequilibrium (LD) with rs10490924 (r2 = 1) showing associations 
with all stages of AMD, and strength of association increased with 
increasing severity of AMD. Two common variants in the CFH gene, 
rs10922109 and rs570618 (in high LD with rs1061170, r2 = 1), were 
associated with intermediate and late AMD (p < 0.001) but not early 
AMD. One rare variant in the C3 gene (rs147859257) showed associa-
tion only with late AMD (p < 0.001). All other SNPs analyzed showed no 
statistically significant association with AMD (Table 4). 
3.5. Characteristics by treatment arm 
Baseline characteristics by randomized treatment groups are pre-
sented in Table 5. The groups were well balanced for recognized risk 
factors for AMD, such as age, smoking and sex, the frequencies of the at- 
risk alleles in three known AMD-related genes and for all other char-
acteristics included in the analysis. 
4. Discussion 
AMD complex pathogenesis includes low-grade inflammatory pro-
cess in drusen at the early stages, and hemorrhages, scarring and atro-
phy of the central retina at the late stage of the disease. Anti- 
Table 1 
Baseline characteristics of the ASPREE-AMD sample. 
Number (%) or Median (IQR). N = 4993.  
Characteristic Total No AMD* Early AMD Intermediate AMD Late AMD 
Age at randomization (years) 73.4 (71.5, 76.6) N =
4993 
73.1 (71.4, 76.0) N =
3099 
73.6 (71.5, 77.0) N =
1031 
74.5 (71.9, 78.5) N =
806 
77.3 (74.5, 82.2) N 
= 57 
Age groups at randomization 
(years) 
70–74 3220 (64) 2116 (66) 639 (20) 449 (14) 16 (<0.5) 
75–79 1197 (24) 687 (57) 271 (23) 219 (18) 20 (2) 
80–84 446 (9) 234 (52) 100 (22) 97 (22) 15 (3) 
85+ 130 (3) 62 (48) 21 (16) 41 (32) 6 (5) 
Sex Male 2412 (48) 1616 (67) 428 (18) 345 (14) 23 (1) 
Female 2581 (52) 1483 (57) 603 (23) 461 (18) 34 (1) 
Education (years) <12 2199 (44) 1344 (61) 462 (21) 365 (17) 28 (1) 
≥ 12 2794 (56) 1755 (63) 569 (20) 441 (16) 29 (1) 
BMI groups Underweight 69 (1) 40 (58) 20 (29) 6 (9) 3 (4) 
Normal 1146 (23) 688 (60) 236 (21) 209 (18) 13 (1) 
Overweight 2297 (46) 1426 (62) 489 (21) 359 (16) 23 (1) 
Obese 1462 (29) 932 (64) 282 (19) 230 (16) 18 (1) 
Diabetes No 4497 (90) 2777 (62) 937 (21) 732 (16) 51 (1) 
Yes 496 (10) 322 (65) 94 (19) 74 (15) 6 (1) 
Hypertension No 1335 (27) 822 (62) 288 (22) 209 (16) 16 (1) 
Yes 3658 (73) 2277 (62) 743 (20) 597 (16) 41 (1) 
Smoking History Current 149 (3) 91 (61) 24 (16) 29 (19) 5 (3) 
Former 2030 (41) 1278 (63) 383 (19) 348 (17) 21 (1) 
Never 2814 (56) 1730 (61) 624 (22) 429 (15) 31 (1) 
Alcohol use Current 4054 (81) 2520 (62) 837 (21) 654 (16) 43 (1) 
Former 240 (5) 161 (67) 43 (18) 31 (13) 5 (2) 
Never 699 (14) 418 (60) 151 (22) 121 (17) 9 (1) 
Glucose (mmol/L) Median (IQR) 5.3 (5.0, 5.8) N = 4894 5.4 (5.0, 5.8) N = 3034 5.3 (5.0, 5.8) N = 1017 5.3 (5.0, 5.8) N = 789 5.5 (5.1, 6.0) N = 54 
HDL (mmol/L) Median (IQR) 1.5 (1.2, 1.8) N = 4858 1.5 (1.2, 1.8) N = 3013 1.6 (1.3, 1.9) N = 1004 1.6 (1.3, 1.9) N = 786 1.5 (1.4, 1.9) N = 55 
LDL (mmol/L) Median (IQR) 3.0 (2.4, 3.6) N = 4842 3.0 (2.4, 3.6) N = 3000 3.0 (2.5, 3.6) N = 1002 3.0 (2.4, 3.6) N = 785 3.0 (2.5, 3.4) N = 55 
Cholesterol total 
(mmol/L) 
Median (IQR) 5.2 (4.5, 5.8) N = 4938 5.1 (4.5, 5.8) N = 3063 5.3 (4.6, 5.8) N = 1020 5.1 (4.6, 5.9) N = 799 5.2 (4.6, 5.8) N = 56 
Previous regular use of 
aspirin 
No 4649 (93) 2912 (63) 943 (20) 740 (16) 54 (1) 
Yes 344 (7) 187 (54) 88 (26) 66 (19) 3 (1) 
Use of any statin No 3461 (69) 2136 (62) 726 (21) 559 (16) 38 (1) 
Yes 1532 (31) 963 (63) 305 (20) 247 (16) 19 (1) 
Awareness of having AMD No 2701 (94) 1718 (64) 560 (21) 415 (15) 8 (<0.3) 
Yes 127 (4) 31 (24) 17 (13) 45 (35) 34 (27)  
Unsure 40 (1) 23 (57.5) 3 (7.5) 14 (35) 0 (0) 
Percentages are presented in column for Totals and by rows for the breakdown of AMD status. In some lines the total does not add up to 100% because of rounding. * - 
‘No AMD’ category combines the cases from the Beckman categories None and Normal Ageing Changes. 
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inflammatory property of aspirin could reduce low-grade inflammation 
in the earlier stages of AMD [9–15], thereby possibly preventing its 
progression to late AMD, whilst its inhibitory effect on platelet aggre-
gation could exacerbate retinal hemorrhages in late AMD [16–21]. To 
date the evidence on the effect of aspirin on the course of AMD is mixed, 
with inconsistent results related to risks and benefits of aspirin in AMD 
from observational and experimental studies [14–19,21–34] and no 
definitive conclusions in meta-analyses [20,35–37], which highlighted 
the need for a well-designed randomized controlled clinical trial of 
sufficient size and duration [38–42]. 
The opportunity to conduct such a trial materialized by conducting 
assessment of the retina status in participants from the major interna-
tional ASPirin in Reducing Events in the Elderly (ASPREE) clinical trial, 
which investigated the effect of aspirin on the health of older people. As 
retinal photography and AMD grading required substantial additional 
effort and resources, they were funded separately as the ASPREE-AMD 
sub-study, a randomized, placebo controlled trial of almost five thou-
sand participants, to examine associations between the incidence and 
progression of AMD and the use of low-dose aspirin. Three landmark 
ASPREE papers reported that aspirin use did not prolong disability-free 
survival in the elderly, but led to a higher rate of major hemorrhages and 
higher all-cause mortality than in the placebo group [45–47], therefore 
the intervention phase of the trial was ceased after a median 4.7 (IQR, 
3.6, 5.7) years of follow-up. The observation of the participants’ health 
conditions continued. 
Analysis of the ASPREE-AMD study cohort of 4993 people, majority 
Table 2 
Univariable multinomial logistic regression analysis of the associations between baseline characteristics and AMD stages.  
Characteristic Early AMD Intermediate AMD Late AMD 
Age at randomization (years) 1.03 (1.01, 1.05) 1.08 (1.06, 1.10) 1.21 (1.16, 1.27) 
Age groups at randomization 70–74 ref ref ref 
75–79 1.31 (1.11, 1.54) 1.50 (1.25, 1.80) 3.85 (1.98, 7.47) 
80–84 1.42 (1.10, 1.82) 1.95 (1.51, 2.53) 8.48 (4.14, 17.37) 
85+ 1.12 (0.68, 1.85) 3.12 (2.07, 4.68) 12.80 (4.84, 33.82) 
Sex Female 1.54 (1.33, 1.77) 1.46 (1.25, 1.70) 1.61 (0.94, 2.74) 
Education (years) ≥ 12 0.94 (0.82, 1.09) 0.93 (0.79, 1.08) 0.80 (0.47, 1.34) 
BMI groups Underweight 1.46 (0.84, 2.54) 0.49 (0.21, 1.18) 3.97 (1.09, 14.49) 
Normal ref ref ref 
Overweight 1.0 (0.83, 1.20) 0.83 (0.68, 1.01) 0.85 (0.43, 1.70) 
Obese 0.88 (0.72, 1.08) 0.81 (0.66, 1.00) 1.02 (0.50, 2.10) 
Diabetes  0.87 (0.68, 1.10) 0.87 (0.67, 1.14) 1.01 (0.43, 2.38) 
Hypertension  0.93 (0.80, 1.09) 1.03 (0.86, 1.23) 0.92 (0.51, 1.64) 
Smoking History Never ref ref ref 
Former 0.83 (0.72, 0.96) 1.10 (0.94, 1.29) 0.92 (0.52, 1.60) 
Current 0.73 (0.46, 1.16) 1.29 (0.84, 1.98) 3.07 (1.16, 8.07) 
Alcohol use Never ref ref ref 
Former 0.74 (0.50, 1.09) 0.67 (0.43, 1.03) 1.44 (0.48, 4.38) 
Current 0.92 (0.75, 1.13) 0.90 (0.72, 1.12) 0.79 (0.38, 1.64) 
Glucose (mmol/L) 0.99 (0.92, 1.06) 0.95 (0.88, 1.04) 1.13 (0.91, 1.39) 
HDL (mmol/L) 1.64 (1.40, 1.92) 1.57 (1.32, 1.86) 2.05 (1.20, 3.50) 
LDL (mmol/L) 0.98 (0.90, 1.06) 0.99 (0.91, 1.09) 0.94 (0.69, 1.29) 
Cholesterol total (mmol/L) 1.06 (0.98, 1.14) 1.05 (0.97, 1.14) 1.03 (0.78, 1.35) 
Previous regular use of aspirin 1.45 (1.12, 1.89) 1.39 (1.04, 1.86) 0.87 (0.27, 2.79) 
Use of any statin 0.93 (0.80, 1.09) 0.98 (0.83, 1.16) 1.11 (0.64, 1.93) 
Awareness of having AMD 1.68 (0.92, 3.06) 6.01 (3.76, 9.61) N/A 
Odds Ratio (95% Confidence interval). ‘No AMD’ was the reference group for all stages of AMD. N = 4993. 
Table 3 
Multivariable multinomial logistic regression analysis of the associations between baseline characteristics and AMD stages.  
Baseline Characteristics Early AMD Intermediate AMD Late AMD 
Age at randomization (years) 1.03 (1.01, 1.05) 1.08 (1.06, 1.10) 1.23 (1.17, 1.30) 
Sex Female 1.37 (1.16, 1.62) 1.35 (1.12, 1.63) 1.32 (0.69, 2.54) 
Education ≥ 12 years 0.95 (0.82, 1.10) 0.98 (0.83, 1.16) 0.87 (0.50, 1.53) 
BMI groups Normal ref ref ref 
Underweight 1.23 (0.70, 2.18) 0.41 (0.17, 1.00) 2.19 (0.45, 10.08) 
Overweight 1.13 (0.93, 1.36) 0.91 (0.74, 1.12) 0.99 (0.48, 2.04) 
Obese 1.02 (0.82, 1.27) 0.93 (0.73, 1.17) 1.42 (0.64, 3.16) 
Diabetes  0.87 (0.63, 1.20) 0.86 (0.60, 1.22) 0.57 (0.18, 1.83) 
Hypertension  0.95 (0.80, 1.12) 0.99 (0.82, 1.19) 0.69 (0.37, 1.29) 
Smoking History Never ref ref ref 
Former 0.88 (0.76, 1.04) 1.27 (1.07, 1.51) 1.22 (0.65, 2.28) 
Current 0.76 (0.47, 1.22) 1.41 (0.90, 2.22) 4.02 (1.42, 11.36) 
Alcohol use Never ref ref ref 
Former 0.89 (0.59, 1.33) 0.69 (0.43, 1.09) 1.86 (0.57, 6.04) 
Current 1.06 (0.85, 1.32) 0.96 (0.76, 1.22) 0.87 (0.40, 1.92) 
Glucose (mmol/L) 1.07 (0.98, 1.18) 1.02 (0.91, 1.14) 1.30 (1.00, 1.70) 
Cholesterol total (mmol/L) 0.93 (0.85, 1.01) 0.95 (0.86, 1.05) 0.92 (0.65, 1.30) 
HDL (mmol/L) 1.52 (1.26, 1.84) 1.43 (1.17, 1.77) 1.96 (1.02, 3.76) 
Previous regular use of aspirin 1.46 (1.11, 1.92) 1.37 (1.01, 1.85) 0.92 (0.28, 3.04) 
Use of any statin 0.87 (0.73, 1.05) 0.94 (0.77, 1.15) 1.11 (0.57, 2.16) 
Odds Ratio (95% Confidence interval). ‘No AMD’ was the reference group for all stages of AMD. N = 4993. 
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of whom (88%) had the baseline retinal images gradable for AMD in 
both eyes, revealed the presence of early, intermediate and late AMD in 
20.6%, 16.1% and 1.1%, respectively. The prevalence of early- 
intermediate AMD stages in the ASPREE-AMD study participants per 
corresponding age group was comparable with three Australian 
population-based AMD studies: the Blue Mountain Eye Study (BMES), 
the Melbourne Visual Impairment Project (Melbourne VIP) and the 
Australian National Eye Health Survey. However, late AMD prevalence 
in ASPREE (1.1%) was lower than that seen in the other studies, which 
reported on prevalence of 4.8% (in participants aged 64 years or older) 
in BMES [64], of about 4% in the 70–79 age group (increasing to 23% in 
those aged 90+) in the Melbourne VIP [65], and of 2% in the 70+ age 
group (nonindigenous participants) in the Australian National Eye 
Health Survey [66]. Most likely, this lower prevalence was due to the 
ASPREE eligibility criteria that limited enrolment to generally healthy 
older individuals, rather than being population-based, and not including 
nursing home residents, thus potentially excluding those who would be 
more likely to have late AMD. 
In ASPREE-AMD, 7% of the participants used aspirin regularly prior 
to entry into the study. Amongst these individuals the prevalence of 
early and intermediate AMD was higher than in those with no regular 
prior use. There was no difference in rates of late AMD though. The 
strong potential for confounding reinforces the need to conduct the 
ongoing follow-up ASPREE-AMD study, which will provide more robust 
evidence to confirm or refute an association. Longitudinal follow up of 
this cohort has the potential to address important questions that remain. 
In the cross-sectional analysis of the ASPREE-AMD cohort at study 
entry, the prevalence and severity of AMD increased with age. Associ-
ations were also found with female gender, higher HDL levels, current 
smokers, four already identified AMD-related genetic risk variants and 
Table 4 
Frequencies of 40 known genetic risk variants of AMD in the ASPREE-AMD Study participants and their association with AMD stages.  




Minor Allele Frequency by AMD stages Associations with AMD Stages 




N = 2735 
Early AMD 
N = 903 
Intermediate AMD 
N = 705 
Late AMD 
N = 48 
OR p-value OR p-value OR p-value 
rs3750846 ARMS2/ 
HTRA1 
C/T 0.195 0.242 0.289 0.448 1.33 1.6E¡05 1.7 2.5E¡14 3.64 3.9E¡09 
rs570618 CFH T/G 0.359 0.388 0.438 0.635 1.13 0.027 1.39 8.1E¡08 3.19 9.69E¡08 
rs10922109 CFH A/C 0.423 0.401 0.357 0.229 0.91 0.098 0.76 9.0E¡06 0.4 0.0002 
rs147859257 C3 G/T 0.004 0.005 0.006 0.031 1.19 0.664 1.35 0.463 7.86 0.001 
rs2230199 C3 C/G 0.199 0.213 0.235 0.292 1.08 0.246 1.23 0.004 1.63 0.029 
rs6565597 NPLOC4/ 
TSPAN10 
T/C 0.34 0.358 0.346 0.437 1.08 0.157 1.03 0.667 1.51 0.047 
rs11080055 TMEM97/ 
VTN 
A/C 0.471 0.488 0.496 0.573 1.07 0.206 1.11 0.083 1.51 0.048 
rs3138141 RDH5/CD63 A/C 0.223 0.242 0.252 0.302 1.11 0.093 1.18 0.02 1.52 0.066 
rs62247658 ADAMTS9- 
AS2 
C/T 0.413 0.410 0.414 0.333 0.99 0.85 1.01 0.924 0.71 0.117 
rs11884770 COL4A3 T/C 0.265 0.277 0.247 0.198 1.06 0.325 0.91 0.16 0.69 0.143 
rs35292876 CFH T/C 0.007 0.009 0.016 0.021 1.22 0.513 2.17 0.004 2.93 0.146 
rs429358 APOE C/T 0.133 0.136 0.104 0.083 1.03 0.732 0.75 0.003 0.59 0.153 
rs2740488 ABCA1 C/A 0.269 0.293 0.282 0.333 1.13 0.045 1.07 0.348 1.36 0.162 
rs7803454 PILRB/PILRA T/C 0.179 0.192 0.209 0.125 1.09 0.235 1.22 0.009 0.65 0.169 
rs12019136 RAD51B A/G 0.045 0.044 0.040 0.021 0.97 0.801 0.89 0.442 0.45 0.266 
rs140647181 COL8A1 C/T 0.018 0.017 0.021 0.031 0.96 0.832 1.2 0.401 1.79 0.334 
rs943080 VEGFA C/T 0.497 0.506 0.501 0.448 1.04 0.493 1.02 0.798 0.82 0.341 
rs1626340 TGFBR1 A/G 0.223 0.209 0.212 0.187 0.92 0.211 0.94 0.384 0.81 0.41 
rs72802342 CTRB2/ 
CTRB1 
A/C 0.080 0.074 0.073 0.062 0.92 0.404 0.9 0.361 0.76 0.518 
rs73036519 APOE C/G 0.294 0.306 0.298 0.323 1.06 0.362 1.02 0.795 1.14 0.545 
rs5754227 SYN3/TIMP3 C/T 0.1355 0.139 0.1121 0.1146 1.03 0.708 0.81 0.022 0.83 0.559 
rs2842339 RAD51B G/A 0.0885 0.0941 0.0844 0.1042 1.07 0.461 0.95 0.626 1.2 0.589 
rs114092250 PRLR/SPEF2 A/G 0.0294 0.0288 0.022 0.0208 0.98 0.888 0.74 0.13 0.7 0.621 
rs10033900 CFI T/C 0.4879 0.4751 0.4872 0.5104 0.95 0.339 1 0.962 1.1 0.657 
rs9564692 B3GALTL T/C 0.2868 0.2957 0.2865 0.2708 1.04 0.472 1 0.982 0.92 0.732 
rs61941274 ACAD10 A/G 0.0165 0.0188 0.0213 0.0208 1.14 0.506 1.29 0.222 1.26 0.743 
rs8135665 SLC16A8 T/C 0.2 0.1977 0.1936 0.2083 0.99 0.832 0.96 0.597 1.05 0.842 
rs10781182 MIR6130/ 
RORB 
T/G 0.3044 0.2918 0.344 0.3125 0.94 0.309 1.2 0.004 1.04 0.864 
rs12357257 ARHGAP21 A/G 0.2245 0.2287 0.1965 0.2188 1.02 0.711 0.84 0.023 0.97 0.893 
rs148553336 CFH C/T 0.0093 0.0127 0.0121 0.0104 1.36 0.216 1.29 0.361 1.12 0.913 
rs55975637 COL8A1 A/G 0.1122 0.1312 0.1241 0.1146 1.2 0.029 1.12 0.212 1.02 0.943 
rs1142 KMT2E/ 
SRPK2 
T/C 0.3523 0.361 0.383 0.3542 1.04 0.507 1.14 0.035 1.01 0.97 
rs2043085 LIPC T/C 0.3943 0.3715 0.3801 0.3958 0.91 0.084 0.94 0.331 1.01 0.976 
rs2070895 LIPC A/G 0.2199 0.2248 0.2113 0.2188 1.03 0.6667 0.95 0.487 0.99 0.978 
rs17231506 CETP T/C 0.3221 0.3389 0.3227 0.3229 1.08 0.191 1 0.968 1 0.987 
rs62358361 C9 T/G 0.0101 0.0072 0.0128 0 0.72 0.281 1.26 0.387 NA NA 
rs141853578 CFI T/C 0.0007 0.0011 0.0014 0 1.52 0.631 1.94 0.444 NA NA 
rs191281603 CFH G/C 0.0048 0.0083 0.0057 0 1.71 0.092 1.18 0.669 NA NA 
rs181705462 C2/CFB/ 
SKIV2L 
T/G 0.0095 0.0089 0.0085 0 0.93 0.806 0.89 0.727 NA NA 
rs121913059 CFH T/C 0.0002 0.0006 0 0 3.03 0.433 NA NA NA NA 
Abbreviations: SNP: Single Nucleotide Polymorphism, A1: Minor Allele, A2: Major Allele, OR: odd ratio, P values: Logistic regression p value. 
* - ‘No AMD’ category combines the cases from the Beckman categories None and Normal Ageing Changes. ‘No AMD’ was the reference group for all stages of AMD. 
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prior use of aspirin. The majority of these findings replicate results from 
previously published Australian studies [64–66]. 
It is of interest that this study also identified that higher HDL levels 
were associated with prevalent AMD, when higher HDL is considered a 
beneficial factor for cardiovascular disease. This finding has been re-
ported in other studies and as yet no good rationale has been put forward 
[67–71]. Higher levels of HDL have been associated with a range of 
factors, including high levels of physical activity and intake of olive oil 
and fatty fish, all of which have previously been reported to be poten-
tially protective for AMD [72–77]. Further work on this interesting, yet 
counter-intuitive association is needed, including studying behavioral 
changes in older age. 
The ASPREE-AMD study did not find associations between AMD and 
alcohol intake, unlike other studies [78–81], however not all studies 
have reported such associations [82–84]. We were unable to detect any 
association between taking statins and AMD, where previous reports 
have been contradictory [61,85]. It must be remembered that in ASPREE 
the cohort was required to be healthy on entry and potential participants 
were excluded if they had some pre-existing chronic illnesses. This dif-
ference from other population-based or cohort studies is likely to have a 
significant impact on disease associations in cross-sectional mode. 
Genetic data was available on the majority (88%) of participants, 
and we found significant associations with four of the previously 
described AMD genetic risk loci ARMS2/HTRA1, CFH and C3 [59]. 
However, beyond these variants, we were unable to replicate other AMD 
risk variants associated with the disease, likely due to the small number 
of samples in each AMD group and absence of the 12/52 AMD risk 
variants in the microarray of the whole ASPREE cohort. 
4.1. Strengths and limitations 
The strengths of this study include its randomized controlled design, 
the age brackets appropriate for AMD, recruitment in both urban and 
rural areas, comprehensive interviews and general examinations via the 
ASPREE study, high quality digital fundus photography, genotyping and 
a relatively large sample size. The proportion of the participants from 
regional centers and rural areas (31%) was similar that in the total 
Australian population (29%), which increases the external validity of 
ASPREE-AMD’s findings. 
The proportion of ungradable images in one eye (11.2%) or both eyes 
(7.4%) was relatively low, compared to other non-mydriatic photog-
raphy studies [66,86,87]. 
A limitation of the ASPREE-AMD study is the use of only non- 
mydriatic color photography to document AMD with no multimodal 
imaging available. However, it was not logistically feasible to provide 
multimodal imaging equipment to the large number of geographically 
Table 5 
Baseline characteristics of the ASPREE-AMD sample by treatment arms. Number (%) or Median (IQR). N = 4993.  
Characteristic Total Placebo Aspirin 
Age at randomization (years) 73.4 (71.5, 76.6) N = 4993 73.3 (71.5, 76.5) N = 2457 73.5 (71.5, 76.8) N = 2536 
Age groups at randomization(years) 70–74 3220 (64) 1602 (65) 1618 (64) 
75–79 1197 (24) 577 (23) 620 (24) 
80–84 446 (9) 215 (9) 231 (9) 
85+ 130 (3) 63 (3) 67 (3) 
Sex Male 2412 (48) 1174 (48) 1238 (49) 
Female 2581 (52) 1283 (52) 1298 (51) 
Education (years) <12 2199 (44) 1102 (45) 1097 (43) 
≥ 12 2794 (56) 1355 (55) 1439 (57) 
BMI groups Underweight 69 (1) 34 (1) 35 (1) 
Normal 1146 (23) 538 (22) 608 (24) 
Overweight 2297 (46) 1130 (46) 1167 (46) 
Obese 1462 (29) 744 (30) 718 (28) 
Diabetes No 4497 (90) 2211 (90) 2286 (90) 
Yes 496 (10) 246 (10) 250 (10) 
Hypertension No 1335 (27) 647 (26) 688 (27) 
Yes 3658 (73) 1810 (74) 1848 (73) 
Smoking history Current 149 (3) 73 (3) 76 (3) 
Former 2030 (41) 983 (40) 1047 (41) 
Never 2814 (56) 1401 (57) 1413 (56) 
Alcohol use Current 4054 (81) 1997 (81) 2057 (81) 
Former 240 (5) 109 (4) 131 (5) 
Never 699 (14) 351 (14) 348 (14) 
Glucose (mmol/L) 5.3 (5.0, 5.8) N = 4894 5.3 (5.0, 5.8) N = 2411 5.3 (5.0, 5.8) N = 2483 
HDL (mmol/L) 1.5 (1.2, 1.8) N = 4858 1.5 (1.2, 1.8) N = 2387 1.5 (1.2, 1.8) N = 2471 
Cholesterol total (mmol/L) 5.2 (4.5, 5.8) N = 4938 5.2 (4.6, 5.8) N = 2435 5.1 (4.5, 5.8) N = 2503 
Previous use of aspirin No 4649 (93) 2298 (94) 2351 (93) 
Yes 344 (7) 159 (6) 185 (7) 
Use of any statin No 3461 (69) 1739 (71) 1722 (68) 
Yes 1532 (31) 718 (29) 814 (32) 
AMD status None/Normal aging (No AMD) 3099 (62) 1536 (62) 1563 (61) 
Early 1031 (21) 509 (21) 522 (21) 
Intermediate 806 (16) 381 (16) 425 (17) 
Late 57 (1) 31 (1) 26 (1) 
ARMS2/HTRA1 rs3750846 CC 210 (5) 109 (5.1) 101 (4.5) 
CT 1534 (35) 754 (35) 780 (35) 
TT 2647 (60) 1282 (60) 1365 (61) 
CFH rs570618 GG 1705 (39) 840 (39) 865 (39) 
TG 2028 (46) 985 (46) 1043 (46) 
TT 658 (15) 320 (15) 338 (15) 
C3 rs147859257 GT 43 (1.0) 19 (0.9) 24 (1.1) 
TT 4348 (99) 2126 (99) 2222 (99) 
Awareness of having AMD Unsure 40 (1) 15 (1) 25 (2) 
No 2701 (94) 1326 (94) 1375 (94) 
Yes 127 (4) 63 (4) 64 (4)  
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distant sites and we believe that much can still be learnt from the high- 
quality color fundus images. Another limitation is the potential to miss 
the diagnosis of neovascular AMD given the widespread use of anti- 
VEGF drugs, which can mask the neovascular complications. To ensure 
we capture virtually all cases of neovascular AMD, we will obtain in-
formation on treatment with anti-VEGF medications via data linkage 
with the Australian Government’s Pharmaceutical Benefit Scheme. Data 
on the use of anti-VEGF treatment will be integrated with extensive 
ASPREE study data for analysis. 
The ENVISion and SNORE sub-studies that provided retinal images 
from 548 (11.0%) and 331 (6.6%) participants, respectively, had addi-
tional exclusion criteria related to MRI, such as the presence of metal 
implants or claustrophobia, which may have meant that their cohorts 
are not as representative of the wider population. We anticipate no 
significant influence of this difference, but this will be investigated when 
considering the results and sensitivity analyses will be undertaken with 
and without including these cases. 
Due to the wealth of other high quality data collected in ASPREE and 
its 15 sub-studies, related to cardiovascular health, depression, demen-
tia, obstructive sleep apnea, frailty, genetic predisposition, social ac-
tivity, dietary specifics, and more, there will be opportunities to explore 
additional associations with the development and progression of AMD. 
The ASPREE-AMD study results, analyzed in the context of the primary 
outcomes of the ASPREE trial and its sub-studies focused on various 
conditions of old age might help to find an optimal balance between 
risks and benefits of low dose aspirin treatment. The results may further 
refine medical recommendations about the use of aspirin in cases where 
AMD is combined with other diseases/conditions. 
5. Conclusion 
The ASPREE-AMD study leveraged opportunities offered by the 
large-scale, randomized, double-blinded primary prevention ASPREE 
trial, to recruit 4993 participants for 5 years of follow up to investigate 
the effect of long-term low-dose aspirin on incidence and progression of 
AMD. Prevalence of the early/intermediate stages of AMD was similar to 
that in the corresponding age groups from the three Australian 
population-based studies, while prevalence of late AMD was lower. 
Associations between AMD and age, current smoking, higher HDL levels, 
female sex and previous regular aspirin use were similar to that expected 
in this population of otherwise healthy elderly participants. Strong ge-
netic associations of AMD with variants of ARMS2/HTRA1, CFH and C3 
genes were consistent with previous associations. Importantly, the 
randomization into treatment groups resulted in well balanced study 
arms with respect to known AMD risk factors and as such will provide an 
excellent opportunity to study the associations of long-term aspirin with 
the incidence and/or progression of AMD. 
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